Kornimate/medical-research-clean huggingface dataset:
cognitive impairments in psychotic disorders

Conditions: Psychotic Disorders; Cognitive Impairment

Summary: patients with psychotic disorders (schizophrenia, bipolar disorder and schizoaffective disorder) often suffer from significant cognitive impairments, however how these develop and change over time before and after the first psychotic break is unclear. while there are data by several groups, showing that many future patients have significant cognitive impairments years before the onset of psychosis, many future patients seem to be doing well before the manifestation of psychosis, and decline steeply in functioning after their first psychotic episode. hence the timing of the onset of cognitive impairment in patients with psychotic disorders requires further exploration. the current study will investigate the timing of cognitive impairment by using iq tests before and after the first psychotic break

in this study the investigators aim to use the dapar tests (a cognitive assessment which all 17 year old jewish adolescents in israel undergo to participate in mandatory military service), which measures intelligence, and is equivalent to the iq test. the subjects will be persons who had their first psychotic break, at least one year following the dapar tests. as part of the study, the participants will re-take the dapar tests, after the onset of the psychotic illness.

Eligibility criteria:
inclusion criteria - study group: * patients between the ages 27-18 who had first psychotic break in the last ten years, and more than a year from the date of the dapar tests. * diagnoses of schizophrenia, bipolar disorder or schizoaffective disorder according to dsm-5 criteria. * previous dapar tests at the age of 17. inclusion criteria - control group: * participants between the ages of 27-18. * no history of psychotic break. * previous dapar tests at the age of 17. exclusion criteria - both groups: * participants who did not perform the full battery of the dapar tests. * participants who have been appointed a guardian. exclusion criteria - control group: - participants who have a first-degree relative who suffers from a psychotic disorder.

Keywords: schizophrenia affective disorders iq tests psychotic disorders cognition
serum endocan levels in polycystic ovary syndrome

Conditions: Polycystic Ovary Syndrome

Summary: in this study the investigators aimed to investigate whether there is a relation between polycystic ovary syndrome and serum endocan levels.

polycystic ovary syndrome is a disorder which is associated with insulin resistance, diabetes, obesity, and cardiovascular disease. endothelial dysfunction, which is known to be an early marker of atherosclerosis, has also been shown to have an association with poycystic ovary syndrome. in this study the investigators aimed to investigate whether there is a relation between polycystic ovary syndrome and serum endocan levels. for this purpose the investigators designed a prospective study including two groups. the diagnosis of polycystic ovary syndrome was made in the presence of ;oligo- and/or anovulation,clinical hyperandrogenism and polycystic ovaries. clinical hyperandrogenism was defined by the presence of hirsutism , acne, or the presence of androgenic alopecia, body mass index (bmi) was calculated as weight in kilograms divided by the square of height in meters. the two groups are compared considering their serum endocan levels,follicle stimulating hormone (fsh), luteinizing hormone (lh), dihydroepiandesterone sulphate (dheas), total testesterone (tt), estradiol (e2) and thyroid stimulating hormone (tsh), fasting blood glucose, triglyceride, total cholesterol, high density lipoprotein, low density lipoprotein, and c-reactive protein (crp) levels.

Eligibility criteria:
inclusion criteria: * 18 to 45 years * patients diagnosed with pcos according to rotterdam criteris (for the study group) * patients without pcos and menstrual irregularities (for the control group) * absence of significant abnormalities on physical examination except hirsutism * no lipid lowering, hypoglycemic, antihypertensive or hormone replacement therapy * normal thyroid function and prolactin level * absence of history or evidence of metabolic, cardiovascular, respiratory or hepatic disease exclusion criteria: * pregnant * ovarian tumors * endocrine diseases (cushing disease, 21-hydroxylase enzyme deficiency, thyroid dysfunction,hyperprolactinemia,diabetes) * chronic diseases (renal insufficiency, cardiovascular, hepatic disease) * oral contraceptive use, anti-androgenic,glucocorticoid, anti-hypertansive- anti-diabetic drug use * smoking or alcohol use
a study of retatrutide (ly3437943) in participants with type 2 diabetes mellitus who have obesity or overweight

Conditions: Type 2 Diabetes; Obesity; Overweight; Obstructive Sleep Apnea

Summary: the purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (j1i-mc-gzbk master protocol) including a subset of participants who have obstructive sleep apnea (osa) (j1i-mc-gsa2). the study will last about 89 weeks and will include up to 24 visits.


Eligibility criteria:
inclusion criteria: * have a body mass index (bmi) greater than or equal to 27.0 kilogram/square meter (kg/m ²) * have type 2 diabetes (t2d) * are on stable treatment for t2d for at least 90 days * have a history of at least one unsuccessful dietary effort to lose body weight. gsa2 inclusion criteria * previously diagnosed with osa * have ahi ≥15 on polysomnography at screening (definition of moderate-to-severe osa) * for participants not on positive airway pressure (pap) therapy: unable or unwilling to use pap therapy and have not used pap for at least 4 weeks prior to screening. * if on pap therapy, have been on pap therapy for at least 3 consecutive months prior to screening, and willing to temporarily stop using pap therapy for approximately 7 days prior to each of the sleep study (psg) visits. exclusion criteria: * have a self-reported or documented change in body weight \>5 kg (11 pounds) within 90 days. * have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening. * have a prior or planned surgical treatment for obesity. * have type 1 diabetes * have a family or personal history of medullary thyroid carcinoma (mtc) or multiple endocrine neoplasia syndrome type 2 (men-2) * have had pancreatitis gsa2 exclusion criteria * use stimulants (for example, modafinil, armodafinil, solriamfetol, pitolisant, amphetamine) less than 3 months prior to screening. * use hypnotics, mirtazapine, opioids, trazodone, and zonisamide less than 3 months prior to screening. * use a dental appliance or other device to treat osa other than pap therapy.
fractional laser as treatment option for various pigment disorders (fractional-3)

Conditions: Pigmentation Disorder

Summary: the purpose of this study is to determine whether the use of non-ablative fractional laser is safe and effective in the treatment of melasma.


Eligibility criteria:
inclusion criteria: * melasma * subjects attending the outpatient department of the netherlands institute for pigment disorders * age at least 18 years * subject is willing and able to give written informed consent exclusion criteria: * use of bleaching creams during the past six weeks * history of keloid * active eczema * suspected hypersensitivity to lidocaine or triple therapy * use of isotretinoin in the past six months * high exposure of the lesion to sunlight or uv light (uva or uvb).

Keywords: fractional laser melasma topical bleaching
diagnostic yield of transbronchial cryobiopsy in diagnosis of interstitial lung diseases

Conditions: Interstitial Lung Disease

Summary: evaluation of diagnostic yield, feasibility and safety of transbronchial lung cryobiopsies done via bronchoscopy in the investigation of interstitial lung disease in comparison with videothoracoscopy-assisted surgical lung biopsy.

see above

Eligibility criteria:
inclusion criteria: * volunteer subjects with interstitial lung disease in whom a surgical lung biopsy is planned for diagnostic investigation. exclusion criteria: * aged less than 18 y.o. * pregnancy * known coagulatoin disorder or blood dyscrasia * aaking antiplatelet agents other than aspirin or therapeutic anticoagulants drugs that cannot be safely discontinued to undergo lung biopsy * arterial oxgen pressure less than 60 mmhg on more than 2 liters per minute oxygen * known pulmonary hypertension defined as systolic pap above 40 mmhg on echocardiography * unable to provide informed consent

Keywords: ild pulmonary fibrosis cryobiopsy transbronchial
evaluation of the fundoplicature of the excluded stomach post omega bypass

Conditions: Bypass, Gastric

Summary: the purpose of this study is to evaluate the efficacy of fundoplication with stomach excluded in the suppression of disabling gastroesophageal reflux requiring surgery in patients who have undergone one anastomosis gastric bypass, with complete objective evaluation of reflux.

the fee\& rgoic trial is a single-center, ambispective, interventional, non-randomized pilot study to evaluate the efficacy of fundoplicature with stomach excluded objectively and comprehensively in the treatment of disabling gastroesophageal reflux requiring gastric bypass after anastomosis. the strategy under study is objective reflux suppression after fundoplication with the stomach excluded in the following specific context: treatment of disabling gastroesophageal reflux requiring post-bypass surgery in omega. the eligible study population will be any adult patient at the investigating center who has undergone one-anastomosis gastric bypass surgery followed by fundoplication of the excluded stomach as part of treatment for disabling post-bypass gastro-oesophageal reflux, resistant to medical treatment and requiring surgery.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years; * patient operated for one anastomosis gastric bypass followed by fundoplicature with stomach excluded for disabling gastroesophageal reflux requiring surgery within 2 years prior to inclusion; * patient in failure of medical treatment; * weight loss greater than 50% of excess weight; * patient with preoperative objective investigations (gastrojejunal fibroscopy, ph-impedancemetry, abdominal ct scan) of gastroesophageal reflux disease; * patient able to understand study-related information and to complete quality-of-life questionnaires in the opinion of the investigator; * patient willing to accept study evaluations; * for women of childbearing age, effective contraception for the duration of the study or negative blood pregnancy test; * patient has been informed and has given free, informed and written consent. exclusion criteria: * patient with conversion from one anastomosis gastric bypass to y bypass for disabling gastroesophageal reflux requiring surgery; * patient with concomitant hiatal hernia correction for one anastomosis gastric bypass ; * patient with secondary one anastomosis gastric bypass ; * patient with a deregulated diet; * patient under legal protection, or deprived of liberty by judicial or administrative decision; * patient unable to understand study information for linguistic, psychological, cognitive or other reasons; * women who are or may become pregnant, of childbearing age, without effective contraception or who are breast-feeding; * patient participating in another clinical trial, or in a period of exclusion from another clinical trial that could interfere with the results of the present study; * patient not covered by a social security scheme.
validating a modified compass 31questionnaire for treatment outcomes

Conditions: Headache, Migraine; Persistent Post Traumatic Headache; Cervicogenic Headache

Summary: eligible participants will complete the compass 31 (year), modified compass 31(one month) and the nsi (one month) questionnaires at baseline and complete the modified compass 31 and the nsi after usual care of treatment. the investigators will 1. compare results for the compass 31(year) to the modified compass 31(month) at baseline. 2. compare modified compass 31(month) to the nsi at baseline and post intervention.

the composite autonomic symptom score (compass 31) is a validated questionnaire designed to measure self reported autonomic symptoms in the last year in individuals with migraine and post-concussive symptoms. in order to use this questionnaire to measure response to treatment it would be preferable to determine if the results of the compass 31 are similar if the patient is asked to complete this thinking about symptoms in the last year as per the usual questionnaire, compared to a modified compass 31 where symptoms in the past month will be assessed. this prospective trial will compare results of the compass 31 (year) to the modified compass 31 (month). since the present gold standard for outcome measures in post-concussive treatment is the neurobehavioral symptom inventory (nsi), this study will also compare results of the modified compass 31(month) to the nsi outcome measure at baseline and post treatment to validate the utilization of the modified version of the compass 31(month) for use in the post-concussive population as an outcome measure for self-reported autonomic nervous system symptoms.

Eligibility criteria:
inclusion criteria: * patients who present to the bamc_birs clinic for treatment of headache between the ages of 18-64. exclusion criteria: * normal composite autonomic symptom score.
efficacy and safety of calcipotriol plus betamethasone dipropionate gel for up to a year in scalp psoriasis

Conditions: Psoriasis of Scalp

Summary: the purpose of the trial is to study the safety and efficacy of long term use of once daily applications, as needed, of calcipotriol plus betamethasone dipropionate gel, as compared to calcipotriol alone in the same gel. the primary response criteria will be the incidence of adverse drug reactions of any type, and the incidence of adverse events of concern associated with long-term corticosteroid use on the scalp.


Eligibility criteria:
inclusion criteria: * scalp psoriasis amenable to topical treatment with a maximum of 100 g of study medication per week * clinical signs of psoriasis vulgaris on trunk and/or limbs, or earlier diagnosed with psoriasis vulgaris on trunk and/or limbs * extent of scalp psoriasis involving more than 10% of the total scalp area * disease severity on the scalp graded as moderate, severe or very severe according to the investigator's global assessment of disease severity exclusion criteria: * puva or grenz ray therapy anywhere on the patient within 28 days prior to randomisation * uvb therapy anywhere on the patient within 14 days prior to randomisation * systemic use of biological treatments, whether marketed or not, directed against or with a potential effect on, scalp psoriasis (e.g., alefacept, efalizumab, etanercept, infliximab) within 6 months prior to randomisaiton * systemic treatments with a potential effect on scalp psoriasis vulgaris (e.g., corticosteroids, retinoids, immunosuppressants) within 28 days prior to randomisation * any topical treatment for scalp psoriasis or any other skin disease on the scalp (excluding medicated shampoos, emollients and hair conditioners) within 14 days prior to randomisaiton * topical treatment for other skin disorders with very potent who group iv corticosteroids within 14 days prior to randomisation * planned initiation of, or changes in dose of concomitant medication that could affect scalp psoriasis (e.g., beta blockers, antimalarial drugs, lithium) during the study * current diagnosis of guttate, pustular, exfoliative or erythrodermic psoriasis * patients with any of the following conditions present on the scalp area: viral lesions, fungal and bacterial skin infections, parasitic infections and atrophic skin * known or suspected severe renal insufficiency or severe hepatic disorders * patiens with history/signs/symptoms suggestive of an abnormality of calcium homeostasis associated with clinically significant hypercalcaemia * trial subjects should be using an adequate method of contraception
outcome of endodontic treatment and retreatment with a bioceramic sealer

Conditions: Endodontic Disease; Endodontically Treated Teeth

Summary: this study is a prospective randomized controlled study of patients who come to the university. the aim is to evaluate the success rate of treatment and retreatment of canals using bioroot ™ rcs cement compared with ah plus up to 6 years of follow-up. the null hypothesis is that there will be no statistically significant differences in rates of successful treatment of root canals filled with bioroot ™ rcs compared to gutta-percha and ah plus sealer.


Eligibility criteria:
inclusion criteria: * patients that demonstrate understanding of the study and willingness to participate as evidenced by signing the voluntary informed consent and received a signed and dated copy of the informed consent form. * understands and is willing to comply with all study procedures and restrictions. * not presence of clinically significant and relevant abnormalities of clinical history or oral examination. * diagnosis of irreversible pulpitis or apical symptomatic / asymptomatic periodontitis. * retreatment cases due to an endodontic failure. * single or bi-radicular teeth. exclusion criteria: * general: patients with systemic diseases, diabetes, immunocompromised and pregnant women, or any clinically significant or relevant oral abnormalities. * specific: root resorption, root fractures, impossibility of restoration and cases were primary or secondary root canal treatment is not the treatment of choice.

Keywords: primary root canal treatment secondary root canal treatment outcome root canal sealer
epidermal cell transplantation in vitiligo skin

Conditions: VITILIGO

Summary: the effects of treatment of transplantation of harvested autologous epidermal cells on vitiligo lesions followed by narrow-band uvb will be investigated in a randomized controlled study.

introduction: transplantation of harvested autologous epidermal cells in vitiligo is widely used in vitiligo but randomized controlled trials in the literature investigating the efficacy of these noncultured keratinocyte/melanocyte suspensions are scarce. in addition there are few data regarding the relationship between the cellular contents of epidermal suspensions and the clinical outcome. aim of the study: to perform a prospective, controlled, randomized, intra-individual comparative study in vitiligo lesions treated with epidermal cell transplantation with additional narrow-band uvb treatment using epidermal cell suspensions that have been characterized at the cellular level. study design: grafting with epidermal cells: a superficial skin shaving excision will be obtained from pigmented skin using a dermatome. a cell suspension will be obtained by trypsinisation. vitiligo skin will be dermabraded by erbium: yag laser after local anaesthesia. the cell suspension will be spread on the dermabraded skin area and fixed with dressings. keratinocyte, and melanocyte counts will be performed on an aliquot of the cell suspension. one symmetrical patch of vitiligo will be chosen as control and left untreated. narrow-band uvb treatment: four weeks after transplantation of epidermal cells, the grafted and control patch will be treated by narrow-band uvb. treatment will be performed 2 times a week. narrow-band uvb treatment will be performed for at least 3 months or 24 treatments. evaluation of the treatment success: the grade of pigmentation in all lesions will be evaluated clinically, with photographs. the clinical rating will be performed as follows: 0 = no repigmentation; 1 = 1-25% repigmentation; 2 = 26 to 50% repigmentation; 3 = 51 to 75% repigmentation; and 4 = 76 to 100% repigmentation. the evaluation of the photographs will be performed blinded by physicians not engaged in the treatment phase of the study. in addition the surface of vitiligo patches will be traced on transparent sheets and monitored by planimetry.

Eligibility criteria:
inclusion criteria: * age \> 18yr * stable vitiligo (no lesion since 12 mo) * 2 symmetrical vitiligo patches of at least 10 cm2 * vitiligo requiring uvb treatment * women using a contraceptive exclusion criteria: * history of keloids * history of skin cancer * photosensitivity * positive blood test for hiv, hbv, hvc, or htlv1 * pregnant or breastfeeding women
a phase 2a dose-ranging and pharmacokinetic study of an oral vitamin d compound (dp001) in secondary hyperparathyroidism

Conditions: Secondary Hyperparathyroidism

Summary: this is an open-label, dose-ranging study of the vitamin d analog dp001 in patients with end-stage renal disease (esrd). the primary goals of this 4-week phase 2a study are to identify an appropriate starting dose of dp001 to be used in subsequent studies in this population and for evaluation of pharmacokinetics of dp001 in esrd patients.

vitamin d hormone or analogs, when bound to the vitamin d receptor, suppress pth synthesis by binding to a negative regulatory element in the promoter of the pth gene, and have been used successfully in the clinic to reduce elevated pth levels in dialysis patients and other ckd patients. dp001 is a highly potent vitamin d compound. in two clinical trials testing dp001 in postmenopausal women, oral dp001 reduced pth levels in a dose-dependent manner, with a dose of 220 ng lowering pth by at least 30% in a majority of patients following one or six months of daily dosing. this study is an open-label, dose-ranging study of dp001 in esrd patients with secondary hyperparathyroidism. cohorts of up to 6 patients will be enrolled and administered oral dp001 at 110 ng three times per week for four weeks. laboratory data from each cohort will be assessed and used to determine a dose for the next cohort. up to 5 dose-ranging cohorts will be studied, with the goal of identifying an appropriate dose for a randomized, placebo-controlled study of oral dp001 for 12 weeks. the data will also be used to select an appropriate dose for an additional cohort of 12 open-label patients in the current study in which the pharmacokinetics of dp001 following a single dose and after repeated doses will be studied.

Eligibility criteria:
inclusion criteria: * patient is diagnosed with esrd and must be on hemodialysis 3 times per week for at least 3 months * plasma intact pth value \>/= 300 pg/ml exclusion criteria: * currently taking drugs affecting vitamin d metabolism * history of symptomatic ventricular dysrhythmias, congestive heart failure, angina pectoris, myocardial infarction, coronary angioplasty, or coronary artery bypass grafting * active malignancy * clinically significant liver disease * active infections
ketoprofen gel vs placebo in low back pain

Conditions: Mechanical Low Back Pain

Summary: this study aimed to analyse the analgesic effect of ketoprofen gel in patients presented with mechanical low-back pain to the emergency department.

mechanical low-back pain which warrants immediate pain relief is not an infrequent symptom for emergency department physicians to deal with. parenteral analgesic is the most common drugs for the these patients in emergency department. however, pain killers in gel forms have not been studied sufficiently for ceasing the pain of these patients. this study aimed to analyse the analgesic effect of ketoprofen gel in patients presented with mechanical low-back pain to the emergency department.

Eligibility criteria:
inclusion criteria: * patients over 18 and lower 65 years old * patients presented with mechanical low-back pain exclusion criteria: * pain more than 24 hours * pain lower than with a pain score of 40 mm * allergy to ketoprofen * drug or alcohol addiction * pregnancy and breast feeding

Keywords: mechanical low back pain emergency department ketoprofen gel